Acurx Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of September 30, 2024 and December 31, 2023 were as follows:


	September 30, 2024		December 31, 2023
Accrued research and development	$	2,968,508	$	2,263,934
Accrued compensation expenses		247,210		716,307
Accrued professional fees		83,950		58,388
Other accounts payable and accrued expenses		19,097		3,809
Total	$	3,318,765	$	3,042,438

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of December 31, 2023 and 2022 were as follows:


	December 31, 2023		December 31, 2022
Accrued compensation expenses	$	716,307	$	542,895
Accrued research and development		2,263,934		1,405,536
Accrued professional fees		58,388		83,715
Other accounts payable and accrued expenses		3,809		29,539
Total	$	3,042,438	$	2,061,685